Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Immunization in Older Adults
NCT04507126Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bcg vaccine in Alzheimer's disease (AD), sponsored by Massachusetts General Hospital. Primary endpoints: Median Fold Change of Cytokine Levels at 90 days and Number of Participants With Treatment-Related Adverse Events up to 390 days. Started Mar 2021; status: completed.
02
Drugs
bcg vaccine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04507126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507126.